Canopy Growth (CGC) Non-Current Assets (2017 - 2026)
Canopy Growth (CGC) posted Non-Current Assets of $429.7 million for Q1 2026, down 38.53% sequentially from $699.0 million in Q4 2025, and down 1.05% YoY from $434.3 million in Q1 2025.
Canopy Growth (CGC) Non-Current Assets (2017 - 2026) Analysis & Trends
Canopy Growth has reported Non-Current Assets for 10 years, with the latest figure at $429.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.05% year-over-year to $429.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 18.0% YoY) and the FY2026 annual result came in at $429.7 million, down 1.05% from the prior year.
- Non-Current Assets declined to $429.7 million in Q1 2026 per CGC's latest filing, from $699.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $3.1 billion in Q1 2022 and troughed at $429.7 million in Q1 2026.
- A 5-year average of $941.3 million and a median of $707.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 67.08% in 2023, then climbed 3.16% in 2024.
- Over 5 years, Non-Current Assets stood at $1.3 billion in 2022, then slumped by 46.38% to $707.0 million in 2023, then rose by 3.16% to $729.3 million in 2024, then declined by 4.16% to $699.0 million in 2025, then slumped by 38.53% to $429.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $429.7 million, $699.0 million, and $453.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Canopy Growth | 437.04 Mn | 190.03 Mn | 16.08 Mn | 431.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 431.99 Mn |
| Mar 31, 2026 | 429.70 Mn |
| Dec 31, 2025 | 699.03 Mn |
| Sep 30, 2025 | 453.44 Mn |
| Jun 30, 2025 | 433.97 Mn |
| Mar 31, 2025 | 434.27 Mn |
| Dec 31, 2024 | 729.34 Mn |
| Sep 30, 2024 | 616.27 Mn |
| Jun 30, 2024 | 678.82 Mn |
| Mar 31, 2024 | 689.53 Mn |
| Dec 31, 2023 | 706.97 Mn |
| Sep 30, 2023 | 876.12 Mn |
| Jun 30, 2023 | 973.23 Mn |
| Mar 31, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.32 Bn |
| Sep 30, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | 3.06 Bn |
| Dec 31, 2021 | 3.43 Bn |
| Sep 30, 2021 | 3.17 Bn |